Pfizer, Sanofi-Aventis, Novartis, GlaxoSmithKline, Abbott Laboratories and Merck to Speak at the 9th Polymorphism & Crystallization Scientific Forum
There has been increased focus on using crystals and the ever-changing, sometimes disappearing properties of polymorphs as significant scientific and business opportunities. IQPC’s Polymorphism & Crystallization Scientific Forum, taking place October 25- 27, 2010 in Philadelphia, PA will address these issues.
Attendees will hear the latest pharmaceutical research and scientific advances for polymorphism and crystallization. Topics to be discussed at the event include:
- Polymorphism patent procurement and protection
- Developing new strategies to extend product lifecycles
- Improving pharmaceuticals through co-crystals
- Positioning R&D teams to deliver more timely solutions
- Using Innovative analysis techniques to assure quality along the path to development
- Tablet sticking and picking
The audience for this event comprises of professionals specialising in chemistry, sciences, chemical engineering, physical properties, pre-formulation, drug delivery, pharmaceutics, solid state and toxicology.
Plus, attendees have the opportunity to attend three pre-conference workshops on the following topics:
- Crystal phase screening, selection and optimisation in early stage drug development
- Emergence of new crystal phases during late stage development: impact, management prevention
- Polymorphism as a tool for life cycle extension
The speaker faculty for this event includes: Pfizer, Novartis, Abbott Laboratories, Astrazeneca, GlaxoSmithKline, University of Michigan, Vertex Pharmaceuticals and more.
For more information, visit the website or contact Karen Richardson at email@example.com or (646) 378-6034.
IQPC produces more than 1,500 events annually around the world, and continues to grow. Founded in 1973, IQPC now has offices in major cities across five continents. IQPC leverages a global research base of best practices to produce a cross industry of information-sharing forums.